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MEGALOBLASTIC ANAEMIA 
DUE TO ANTICONVULSANT THERAPY 
PlO MANGION, 
M.D., M.R.C.P. (U.K.), 
Medical Registrar, 
St. Peter's Hospital, 
Chertsey, Surrey. 
Megaloblastic anaemia occurring 
during prolonged anticonvulsant therapy 
was ·first described by Mannheimer et al. 
in 1952. Subsequent studies (Reynolds, 
1968; Klipstein, 1964; Malpas et al., 1966) 
have established that such anaemia is due 
to a Idisturbance of folic acid metabolism 
and may be associated with a variety of 
anticonvulsants. Large-scale surveys have 
revealed that serum and red cell folate 
levels are commonly low in patients on 
anticonvulsant therapy, but a significant 
degree of anaemia is rare. According to 
Wintrobe (1967), less than 100 such pa-
tients have been reported. A case of 
severe megaloblastic anaemia complicat-
ing therapy with phenobarbitone and 
diphenylhydantoin sodium (phenytoin) is 
here described. 
Case Report 
A 41-year old married woman was 
admitted to St. Peter's Hospital, Chertsey, 
Surrey, in November 1970, complaining 
of increasing tiredness, shortness of 
breath and ankle oedema. Since the age 
of 10 she had been suffering from grand 
mal epilepsy which had been treated with 
phenobarbitone 60 mg. t.d.s. and pheny-
toin 100 mg. t.d.s. On this regime she 
had approximately one fit every two 
months. She was one of a pair of identi-
cal twins, and her sister had also deve-
loped epilepsy at the same age. The 
patient had undergone a cholecystectomy 
for gall stones in 1963, and had been 
successfully treated for iron deficiency 
anaemia in 1964. Menstruation had ceased 
in 1968. There had been no children from 
her 16-year marriage. 
Her present symptoms had developed 
insidiously. For two years she had noted 
increasing pallor and tiredness, but only 
over the last three months had she con-
sidered the possibility of physical illness. 
One month before admission she was 
given iron tablets without symptomatic 
improvement. Instead, she developed 
shortness of breath on exert:on, extreme 
fatigue, dizziness, palpitations and ankle 
swelling. She also noted frequent head-
aches, and had increasing difficulty in 
thinking and remembering both recent 
and remote events, but did not complain 
of soreness of the tongue, paraesthesiae, 
unsteadiness in walking, gastro-intestinal 
disturbances, or loss of weight. Three 
days before admission, a doctor had given 
her cyanocobalamin lOOO p.g. intramuscu-
larly, though no haematological investi-
gations had been performed. 
On examination she was a moderately 
obese dyspnoeic woman with striking 
pallor of the mucosae and skin, and there 
were several bruises on the extensor sur-
faces of the arms and shins. The tongue 
was normal. She had a regular full-
volume pulse of 96 per minute, with a 
blood presure of 120/60. The apex beat 
was 8 cm. to the left of the midline, and 
the impulse was hyperdynamic; there was 
an apical triple rhythm with a soft mid-
systolic murmur; the jugular venous pres-
sure was raised to 5 cm., and bilateral 
basal crepitations, a tender enlarged liver 
and sacral and ankle oedema were also 
observed. A firm enlarged spleen was 
felt 6 cm. below the left costal margin. 
Numerous round and flame-shaped hae-
morrhages and soft exudates were seen 
in the optic fundi. The remainder of the 
neurological examination was normal and 
in particular there was no evidence of pe-
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ripheral neuropathy or cerebellar distur-
bances. 
Immediate investigations gave the 
following results: 
Haemoglobin 4.5 G/100 m!. (32%) 
PCV 14%, MCHC 33%, MCV 115 cU.mm. 
Reticulocytes 25% 
White cell count 3000/cu.mm. (neutrophils 
74%, eosinophils 2%) 
Platelet count 65,000/cu.mm. 
The blood smear showed marked aniso-
cytosis, poikilocytosis, a few macrocy-
tes, occasional erythroblasts, and some 
polysegmented neutrophil leucocytes. 
Serum iron 75 p,g/100 ml. Total iron bind-
ing capacity 430 p,g/100 ml. 
Serum folate assay (Lactobacillus casei 
method) 2.3 ng/ml. (normal range 6-20 
ng/ml.) 
Occult blood in faeces negative x 3. 
Serum vitamin B12 assay (Lactobacillus 
leichmanii method) more than 1000 
pg/ml. (normal range 180 - 900 pg/ml.) 
Vitamin B12 absorption normal by the 
Schilling method. 
Chest x-ray - slight enlargement of the 
heart with evidence of pulmonary con-
gestion. 
Blood urea and serum electrolyte levels, 
liver function tests, electrocardiogram 
and urine analysis were all normal. 
Later investigations showed a mildly 
diminished red cell survival time using 
the 51 Cr-Iabelled red cell method. The 
3-day stool fat content and xylose absorp-
tion test were normal. 
A provisional diagnosis of megalo-
blastic anaemia following long-term anti-
convulsant therapy was made. Marrow 
examination was not performed because 
of recent vitamin BI2 medication. It was 
decided to observe the response to this 
and to continue with oral iron therapy but 
not to add folic acid to the treatment im-
mediately. The marked reticulocytosis 
and rising haemoglobin level which oc-
curred during the first week following 
admission is shown in fig. 1. It will be 
seen that during the second week there 
was no further rise in the haemoglobin 
level. Treatment with folic acid 5 mg. 
t.d.s. was now added. This was followed 
by a well-marked reticulocytosis. In the 
first three weeks of folic acid therapy, the 
haemoglobin level rose from 6.3 g/100 
m!. to 10.5 g/100 ml., at which stage she 
was discharged from hospital. Treatment 
by folic acid 5 mg. t.d.s., phenobarbitone 
6c) mg. t.d.s., sulthiame 200 mg. q.d.s. and 
diazepam 10 mg. nocte was continued. 
Initially, treatment was also given for 
congest:ve cardiac failure with satisfac-
tory results. As regards anticonvulsant 
therapy, . phenytoin was discontinued on 
admission to hospital and sulthiame (Os-
polot) in increasing doses substituted. 
There was a deterioration in epileptic 
control, three nocturnal fits occurring in 
the first two weeks. When folic acid 
treatment was started at the end of the 
second week, fits became even more fre-
qeent and on one occasion status epilepti-
cus supervened but was controlled by 
intramuscular paraldehyde. Eventually 
geod control was re-established using 
phenobarbitone 60 mg. t.d.s. and sulthiame 
200 mg q.d.s. together with diazepam 10 
mg. at night. 
When last seen at the outpatient cli-
nic on 24th April 1971 she was well with 
a haemoglobin level of g/100 ml. 
Discussion 
Circumstantial evidence leaves little 
doubt that this patient initially had a 
megaloblastic type of anaemia, although 
it is unfortunate that a diagnostic marrow 
examination was .not performed. The pe-
ripheral blood picture which showed 
severe anaemia, macrocytosis, leucopenia, 
polysegmented neutrophil leucocytes and 
thrombocytopenia was characteristic, and 
the response to cyanocobalamin and later 
to folic acid therapy, in the presence of a 
low serum folate level, was confirmatory. 
The red cell survival studies excluded 
serious haemolytic disease as a cause of 
splenomegaly, and in any case consider-
able splenomegaly may occur in uncom-
plicated megaloblastic anaemia. At out-
patient follow-up some weeks later there 
had been a marked decrease in the size of 
the spleen. Retinal haemorrhages may 
occur with severe anaemia of any type 
but are particularly associated with the 
megaloblastic anaemias and the leukae-
mias, and may be related to the associated 
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thrombocytopoenia. The partial response 
to vitamin Bl2 therapy in the presence of 
a normal vitamin Bl2 absorption was con-
sistent with folate deficiency. There was 
no evidence of other causes of folate defi-
ciency such as poor nutrition, malabsorp-
tion, liver disease or severe haemolytic 
disease. She had never been exposed to 
drugs of the cytotoxic folate-antagonist 
group. There can be little doubt that anti-
convulsant drugs, in the combination of 
phenobarbitone and phenytoin, were res-
ponsible for this patient's haematological 
picture. 
Megaloblastic anaemia is a well-
recognised but rare complication of long-
term treatment with phenobarbitone, 
phenytoin and primidone. Evidence of 
megaloblastic haemopoiesis is commonly 
seen in patients undergoing anticonvul-
sant therapy. A macrocytic blood picture 
has been recorded in 11 - 33% of patients 
on anticonvulsant treatment (Malpas et 
al., 1966; Ibbitson et al., 1967; Hawkins 
and Meynell, 1958) and megaloblastic 
changes on bone marrow examination in 
38% (Reynolds et al., 1966). Serum vita-
min Bl2 levels are almost always in the 
normal range in these patients, though the 
levels are often lower than in control 
subject (Malpas et al., 1966). On the 
other hand, evidence of a disturbance of 
folate metabolism is commonly found. 
Serum folate levels of less than 5 p.gjl00 
m!. in up to 80% of patients on anticon-
vulsant therapy have been reported (Ibbit-
son et al., 1967; Reynolds et al., 1966). 
FIGLU tests are of no value in detecting 
this type of folate deficiency (Reynolds et 
al., 1966). On this evidence it has become 
generally accepted that disturbed folic 
acid metabolism is commonly associated 
with prolonged anticonvulsive treatment. 
This induced folate deficiency rarely leads 
to megaloblastic anaemia, and rather more 
commonly according to some (Reynolds 
et al., 1966), to such other manifestations 
as mental, emotional and behavioural de-
terioration, florid psychiatric disturbances, 
peripheral neuropathy, intestinal malab-
sorption and secondary infertility (Hughes 
J ones, 1968). 
The mechanism of the disturbance of 
folic acid metabolism is obscure. It is 
usually considered to be due to a com-
petitive interaction between the anticon-
vulsant drug or drugs and folic acid (Klip-
stein, 1964; Hawkins and Meynell, 1958; 
Reynolds, 1970). It has also been sug-
gested that the drugs may interfere with 
folate absorption (Hoffbrand and Neche-
les, 1968). There is no evidence that the 
mechanism involves liver enzyme induc-
tion, which is known to occur with some 
drugs, particularly phenobarbitone (Con-
ney, 1967). 
Anticonvulsant-induced anaemia in-
variably responds to treatment with folic 
acid in pharmacological doses (Wintrobe, 
1967). There may also be a partial or 
complete response to treatment with vita-
min Bl2 • This is understandable in view 
of the close association of folic acid and 
vitamin Bl2 in basic biochemical processes. 
In our patient vitamin B12 therapy led to 
a dramatic reticulocytosis but a small rise 
only in the haemoglobin level. A further 
marked and persistent rise followed the 
exhibition of folic acid therapy. 
The institution of folic acid therapy 
in patients with anticonvulsant-induced 
folate deficiency may in turn cause certain 
problems. An increase in the frequency 
or severity of epileptic attacks may be in-
duced, and status epilepticus has been 
observed (Chanarin et al., 1960; Wells, 
1968). It has been suggested that the 
anticonvulsant action of phenobarbitone 
and phenytoin may be at least in part due 
to their effect on folic acid metabolism 
(Reynolds et al., 1966), the low serum 
folate level contributing to adequate con-
trol of the epilepsy. It is possible that 
the temporary deterioration which oc-
curred in our patient may have been re-
lated to the initiation of folic acid therapy 
as well as the discontinuation of pheny-
toin. It is uncertain whether in patients 
with anticonvulsant-induced anaemia, the 
offending anticonvulsants should be dis-
continued and others substituted in addi-
tion to folic acid administration. It is 
usually recommended that the dose of 
these drugs should be reduced to the low-
est compatible with adequate epileptic 
control, as there is some evidence that 
folate deficiency is related to the dose 
(Hawkins and Meynell, 1958) and dura-
tion (Klipstein, 1964) of anticonvulsant 
therapy. In our patient sulthiame, which 
does not appear to interfere with folic 
acid metabolism, was substituted for phe-
nytoin but phenobartitone had to be con-
tinued to control her epileptic attacks. 
It is self evident that folate deficiency 
resulting from anticonvulsant therapy, 
when it causes such serious sequelae as 
megaloblastic anaemia or peripheral neu-
ropathy, must be treated, but does folate 
deficiency per se require treatment? Is 
there a case for the routine administration 
of folic acid supplements in all patients on 
long-term anticonvulsant treatment? The 
answer must depend on how far the anti-
convulsant action is indeed dependent on 
disturbed folate metabolism. It would 
seem that, in the present state of our 
knowledge, supplementary treatment with 
folic acid should be restricted to those 
patients in whom psychiatric or neurolo-
gical disturbances are present, or who 
have developed megaloblastic anaemia. 
All epileptic patients on anticonvulsant 
therapy must therefore be monitored for 
neurological, psychiatric and haematologi-
cal deterioration, so that folic acid supple-
ments may immediately be given if the 
deterioration, which often develops insi-
diously, can be traced to folate deficiency. 
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